HUTCHMED (00013.HK): GSK licence deal for KRAS-EGFR ATTC closes
- The global trial covers unresectable advanced or metastatic solid tumours in China and the United States.
- Beyond the upfront payment, HUTCHMED Limited will receive tiered royalties based on net sales.
NewTimeSpace News: On 21 October 2026, HUTCHMED (China) Limited (stock code: 00013) said the exclusive development and licence agreement between its subsidiary HUTCHMED Limited and a subsidiary of GSK plc closed after customary conditions including antitrust review were met, giving the GSK unit rights to develop and commercialise HMPL-A830 outside the Chinese mainland, Hong Kong, Macao and Taiwan.
HMPL-A830 is a first-in-class antibody-targeted therapy conjugate (ATTC) pairing a potent KRAS small molecule inhibitor payload with an anti-EGFR antibody. A global Phase I trial in unresectable advanced or metastatic solid tumours, run in China and the United States, began its Phase Ia portion in September 2026 (NCT07718581). HUTCHMED Limited will run global Phase I development while the GSK unit handles later development and sales in its territories. HUTCHMED expects a USD 110 million upfront payment shortly plus up to USD 1.185 billion in milestones and tiered royalties on net sales.
- HUTCHMED (00013.HK): Two Phase III Studies Picked for ESMO Orals
- Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904
- HUTCHMED (00013.HK): Licenses global rights to KRAS-EGFR antibody-targeted conjugate HMPL-A830 to GSK for up to USD 1.295 billion
- HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit
- HUTCHMED (00013.HK): ATLED (Fanregratinib) Approved by NMPA for FGFR2 Fusion Cholangiocarcinoma
